An update from Replimune Group (REPL) is now available.
Replimune Group, Inc. has released promising results from their IGNYTE clinical trial, showing that one-third of melanoma patients who had not responded to prior anti-PD1 therapy saw improvement when treated with a combination of RP1 and nivolumab. These findings revealed durable responses exceeding six months and tolerable side effects, primarily of mild grade. The comprehensive data is set to be presented at an upcoming medical congress, highlighting the treatment’s potential in improving outcomes for melanoma patients previously unresponsive to standard therapies.
Find detailed analytics on REPL stock on TipRanks’ Stock Analysis page.
